大株红景天注射液对晚期乳腺癌患者生活质量和免疫功能的影响

苏国新 朱小丽 苏雅萍 李玲玲 陈赫军 种宝贵 马红芳

[摘要] 目的 观察大株红景天注射液联合化疗药物对晚期乳腺癌患者生活质量和免疫功能的影响。 方法 选取2014年6月～2016年6月衡水市哈励逊国际和平医院行化疗药物治疗的分期为Ⅳ期的56例乳腺癌患者，采用随机数字表法分将其为观察组和对照组，每组各28例。两组化疗方案均选择紫杉醇联合顺铂，同时观察组在该化疗方案基础上联合靜脉滴注大株红景天注射液。在治疗2个周期后，对临床治疗效果进行监测和评价。观察两组细胞免疫学相关的指标变化：检测两组治疗前后CD3+、CD4+、CD4+/CD8+、CD8+、NK值。测量两组患者的血常规、肝肾功能及心功能的各项指标，记录治疗期间的药物不良反应情况及分级。 结果 经过2个周期的治疗后，两组CD3+、CD4+、CD4+/CD8+及NK细胞均高于治疗前，CD8+低于治疗前，差异有统计学意义（P < 0.05）。观察组CD3+、CD4+、CD4+/CD8+、NK细胞在治疗后明显高于对照组，CD8+明显低于对照组，差异有统计学意义（P < 0.05）。观察组在联合治疗期间心脏毒性、恶心呕吐的发生率均明显低于对照组，差异有统计学意义（P < 0.05）。观察组生活质量改善情况优于对照组，差异有统计学意义（P < 0.05），但两组之间的疗效比较，差异无统计学意义（P > 0.05）。结论 大株红景天注射液联合化疗药物能够显著改善晚期乳腺癌患者的细胞免疫水平，提高其生活质量。

[关键词] 大株红景天注射液;晚期乳腺癌;免疫功能;生活质量

[中图分类号] R737.9          [文献标识码] A          [文章编号] 1673-7210（2019）07（b）-0133-04

Effects of Sofren Injection on quality of life and immune function in patients with advanced breast cancer

SU Guoxin   ZHU Xiaoli   SU Yaping   LI Lingling   CHEN Hejun   CHONG Baogui   MA Hongfang

Department of Medicine， Hengshui Harrison International Peace Hospital， Hebei Province， Hengshui    053000， China

[Abstract] Objective To observe the effects of Sofren Injection on quality of life and immune function in patients with advanced breast cancer. Methods Form June 2014 to June 2016， 56 cases of breast cancer patients with Ⅳ stage who received chemotherapy treatment in Hengshui Harrison International Peace Hospital were selected and divided into observation group and control group by the random number table method， with 28 cases in each group. Both groups selected Paclitaxel combined with Cisplatin chemotherapy regiments， and the observation group was given Sofren Injection by intravenous drip on the basis of the chemotherapy regiments. After 2 cycles of chemotherapy， the clinical efficacy was monitored and evaluated. The indexes related to cell immunology in the two groups were observed： CD3+， CD4+， CD4+/CD8+， CD8+ and NK values were measured and calculated before and after chemical drug treatment in the two groups. The blood routine， liver and kidney function and cardiac function of the patients were measured， and the adverse drug reactions and grades during the hospitalization were recorded. Results After 2 cycles of treatment， CD3+， CD4+， CD4+/CD8+ and NK cells in the two groups were all higher than those before chemotherapy， and CD8+ was lower than before treatment， with statistically significant differences （P < 0.05）. CD3+， CD4+， CD4+/CD8+ and NK cells in the observation group were significantly higher than those in the control group after treatment， CD8+ was lower than that of the control group， and the difference was statistically significant （P < 0.05）. The incidence of cardiotoxicity， nausea and vomiting in the observation group was significantly lower than that in the control group during the combined treatment， with statistically significant differences （P < 0.05）. The improvement rate of life quality in the observation group was better than that in the control group， and the difference was statistically significant （P < 0.05）. There was no statistically significant difference in efficacy between the two groups （P > 0.05）. Conclusion Large strains of Sofren Injection combined with chemotherapy drugs can significantly improve the cellular immunity and quality of life of patients with advanced breast cancer.